Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Bauer, A; Schreinlechner, M; Sappler, N; Dolejsi, T; Tilg, H; Aulinger, BA; Weiss, G; Bellmann-Weiler, R; Adolf, C; Wolf, D; Pirklbauer, M; Graziadei, I; Ganzer, H; von Bary, C; May, AE; Woll, E; von Scheidt, W; Rassaf, T; Duerschmied, D; Brenner, C; Kaab, S; Metzler, B; Joannidis, M; Kain, HU; Kaiser, N; Schwinger, R; Witzenbichler, B; Alber, H; Straube, F; Hartmann, N; Achenbach, S; von Bergwelt-Baildon, M; von Stulpnagel, L; Schoenherr, S; Forer, L; Embacher-Aichhorn, S; Mansmann, U; Rizzast, KD; Massberg, S

Massberg, S (corresponding author), LMU Univ Hosp Munich, Med Klin & Poliklin 1, Munich, Germany.; Bauer, A (corresponding author), Med Univ Innsbruck, Univ Klin Innere Med 3, Dept Internal Med Cardiol & Angiol 3, A-6020 Innsbruck, Austria.

LANCET RESPIRATORY MEDICINE, 2021; 9 (8): 863

Abstract

Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin......

Full Text Link